| Revenue growth | Q2 +43%, H1 +25% YoY |
|---|---|
| Margins | Q2 gross 71.6% vs 64.1%; reported EBITDA 32.7% |
| Demand visibility | Take-or-pay contracts: 10-yr CDMO, 5-yr insulin DS |
| Management confidence | Confident; no numeric guidance given |
Growth
Q2 revenue +43% to ₹280 Cr; H1 +25% to ₹498 Cr. API H1 +11%; ₹53 Cr milestone revenue.
Outlook
No numeric guidance. DCV commercial supplies next year; CDMO manufacturing starts Q4 FY27; second ANDA Q4 FY27.
Risks
Net debt ₹314 Cr; 61% of ₹1,509 Cr gross capex yet to earn revenue; milestone income non-recurring.
Last quarter's promises, checked
Delivered
- Guided EBITDA margin ~30% → Q2 reported 32.7% (= BEAT)
- Guided gross margin ~60% → Q2 71.6% (= BEAT)
- Guided net debt ~₹326 Cr → ₹314 Cr (= BEAT)
Partly delivered
- Guided FY27 revenue +20% → H1 +25%; full year open (= PARTIAL)
- Guided capex ₹200–250 Cr/yr → H1 ₹113 Cr (= PARTIAL)
- Guided DCV licence signing early Q3 FY27 → unconfirmed (= PARTIAL)
Investor Presentation filed with BSE, NSE: SYMBIOTEC. Summary written with AI assistance from the document.
Symbiotec Pharmalab Ltd: key numbers
- Share price
- ₹1,271.50
- Market cap
- ₹8,170 Cr
- Revenue (annual)
- ₹869.1 Cr
- Net profit (annual)
- ₹109.9 Cr
- Promoter holding
- 33.28%
- FII holding
- 3.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Symbiotec Pharmalab Ltd
All →Symbiotec Pharmalab Results Update
Symbiotec Pharmalab released its Q2 and H1 FY27 investor release, reporting consolidated Q2 revenue of ₹280 crore and PAT of ₹52 crore. The release also cites a ₹53 crore milestone revenue from a US licensing agreement.
Symbiotec Pharmalab Other Announcement
Symbiotec Pharmalab filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing lists promoter and public holdings with no transaction or corporate event.
Symbiotec Pharmalab Board Meeting Date
Symbiotec Pharmalab schedules a 5 November 2026 board meeting to consider unaudited quarterly and half-year results. No amounts are proposed.
Symbiotec Pharmalab Share Pledge
Promoters of Symbiotec Pharmalab submitted a revised disclosure to update the lender and trustee names for their pledged share encumbrance.
Symbiotec Pharmalab Other Announcement
Symbiotec Pharmalab Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with Regulation 31 of the SEBI LODR Regulations.
Symbiotec Pharmalab Other Announcement
Symbiotec Pharmalab has filed the routine quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ending September 30, 2026.